Strides Pharma Science Limited

NSEI:STAR Stock Report

Market Cap: ₹90.2b

Strides Pharma Science Management

Management criteria checks 2/4

Strides Pharma Science's CEO is Badree Komandur, appointed in Jun 2024, has a tenure of 9.08 years. total yearly compensation is ₹58.10M, comprised of 74.9% salary and 25.1% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth ₹53.80M. The average tenure of the management team and the board of directors is 2 years and 7.8 years respectively.

Key information

Badree Komandur

Chief executive officer

₹58.1m

Total compensation

CEO salary percentage74.87%
CEO tenure2yrs
CEO ownership0.06%
Management average tenure2yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Narrative Update • Jun 01

STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook

Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative Update • May 17

STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook

Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
Narrative Update • Apr 28

STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead

Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.
Narrative Update • Apr 13

STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis

Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).
Narrative Update • Mar 30

STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead

Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).
Narrative Update • Mar 16

STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis

Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).
Narrative Update • Sep 05

Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach

With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
User avatar
New Narrative • Feb 10

US Product Launches And ESG Leadership Will Strengthen Future Market Position

Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.
Analysis Article • Nov 01

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...
Analysis Article • Oct 21

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...
Analysis Article • Aug 14

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...
Analysis Article • Apr 04

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...
Analysis Article • Feb 29

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 23

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...
Analysis Article • Sep 26

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jun 08

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Aug 02

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...
Analysis Article • Jun 25

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO Compensation Analysis

How has Badree Komandur's remuneration changed compared to Strides Pharma Science's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

₹6b

Dec 31 2025n/an/a

₹5b

Sep 30 2025n/an/a

₹4b

Jun 30 2025n/an/a

₹3b

Mar 31 2025₹58m₹44m

₹4b

Dec 31 2024n/an/a

₹3b

Sep 30 2024n/an/a

₹2b

Jun 30 2024n/an/a

-₹475m

Mar 31 2024₹44m₹37m

-₹1b

Dec 31 2023n/an/a

-₹2b

Sep 30 2023n/an/a

-₹2b

Jun 30 2023n/an/a

-₹924m

Mar 31 2023₹44m₹36m

-₹2b

Dec 31 2022n/an/a

-₹2b

Sep 30 2022n/an/a

-₹2b

Jun 30 2022n/an/a

-₹4b

Mar 31 2022₹46m₹38m

-₹5b

Dec 31 2021n/an/a

-₹4b

Sep 30 2021n/an/a

-₹3b

Jun 30 2021n/an/a

-₹543m

Mar 31 2021₹44m₹33m

₹3b

Dec 31 2020n/an/a

₹28m

Sep 30 2020n/an/a

₹589m

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹37m₹23m

₹492m

Compensation vs Market: Badree's total compensation ($USD610.17K) is above average for companies of similar size in the Indian market ($USD390.83K).

Compensation vs Earnings: Badree's compensation has increased by more than 20% in the past year.

CEO

Badree Komandur (54 yo)

2yrs
Tenure
₹58,100,000
Compensation

Mr. Badree Komandur had been the Chief Financial Officer and Executive Director of Finance of Strides Pharma Science Limited (formerly known as Strides Shasun Limited) since August 1, 2013 until June 1, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Arun Pillai
Founder & Non-Executive Chairperson36yrs₹90.00m2.24%
₹ 2.0b
Badree Komandur
MD & Group CEO2yrs₹58.10m0.060%
₹ 53.8m
Vikesh Kumar
Group Chief Financial Officer2yrs₹39.93mno data
Manjula Ramamurthy
Compliance Officer & Company Secretary9.3yrs₹10.00mno data
Sormistha Ghosh
Group General Counsel and Chief Risk & Sustainability Officerno datano datano data
Nandini Matiyani
Executive Vice President of Human Resourcesless than a yearno datano data
C. Sundar
Executive Vice President of Operationsno datano datano data
Kevin Cook
Senior Vice President of Strides Pharma Inc.no datano datano data
Venkata Seetharama Pakalapati
Executive Directorno datano datano data
Umesh Kale
Chief Quality Officerno datano datano data
A. Narayanan
Chief Information Technology Officerno datano datano data
Vinod Nair
Senior Vice President of Institutional Businessno datano datano data
2.0yrs
Average Tenure
54yo
Average Age

Experienced Management: STAR's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arun Pillai
Founder & Non-Executive Chairperson36yrs₹90.00m2.24%
₹ 2.0b
Badree Komandur
MD & Group CEO9.1yrs₹58.10m0.060%
₹ 53.8m
Venkata Seetharama Pakalapati
Executive Directorno datano datano data
Homi Khusrokhan
Independent Director9.1yrs₹4.50mno data
Dennis Bastas
Executive Chairman of Arrow Pharmaceuticals Pty Ltdno datano datano data
Ameet Hariani
Independent Director2.3yrs₹800.00kno data
Gopakumar Nair
Member of Scientific Advisory Boardno datano datano data
Elias Neto
Member of Scientific Advisory Boardno datano datano data
S. Vyas
Member of Scientific Advisory Boardno datano datano data
B. Suresh
Member of Scientific Advisory Boardno datano datano data
C. Gupta
Member of Scientific Advisory Boardno datano datano data
Kausalya Santhanam
Independent Director6.5yrs₹4.75m0.0024%
₹ 2.2m
7.8yrs
Average Tenure
65.5yo
Average Age

Experienced Board: STAR's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 08:34
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Strides Pharma Science Limited is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aditya KhemkaAmbit Capital
Harith AhamedAvendus Spark
Prakash AgarwalAxis Capital Limited